Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

7.100 UNCHANGED
Streaming Delayed Price Updated: 2:06 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,347
Open 7.180
Bid (Size) 7.110 (1)
Ask (Size) 7.180 (3)
Prev. Close 7.100
Today's Range 7.100 - 7.180
52wk Range 4.560 - 13.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire

Performance

YTD
-29.7%
-29.7%
1 Month
-5.8%
-5.8%
3 Month
-28.0%
-28.0%
6 Month
+2.9%
+2.9%
1 Year
-29.0%
-29.0%

More News

Read More
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
Examining the Future: MiNK Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For May 15, 2025
Via Benzinga
A Look at MiNK Therapeutics's Upcoming Earnings Report
Via Benzinga
Earnings Scheduled For March 18, 2025
Via Benzinga
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Via Chartmill
These stocks are moving in today's session
Via Chartmill
The market is filled with gapping stocks in Tuesday's session.
Via Chartmill
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 7.100
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 05/23/25 02:06 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.